Trevena, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
  • Pipeline
    • Overview
    • TRV045
    • TRV250
    • TRV734
  • Products
    • OLINVYKâ„¢ (oliceridine) injection
  • Medical Affairs
    • Investigator-Initiated Trials
    • Contact Medical Information
  • Publications
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Financial Info
    • Stock Info
    • Resources
    • Governance
  • Careers
  • Contact
    • Contact Medical Information
    • Whistleblower Hotline

Press Releases

Investors

Investors

  • Overview
  • Press Releases
  • Events & Presentations
    • Presentations
    • IR Calendar
  • Financial Info
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Stock Info
    • Quote
    • Analyst Coverage
    • IRS Form 8937
  • Resources
    • Email Alerts
    • Contacts
    • FAQ
  • Governance
    • Overview
    • Management Team
    • Board of Directors
    • Governance Documents

Trevena CEO to Present at the 2011 UBS Global Life Sciences Conference

Sep 15, 2011 8:00am EDT

Cardiorenal Actions of Trevena Biased Ligand Heart Failure Drug Explained in Mayo Clinic Publication and Presentations

Sep 12, 2011 9:00am EDT

Trevena Receives Major New Award from NIH To Develop Delta Opioid Biased Ligand Drug

Aug 18, 2011 4:51pm EDT

Trevena Names Arthur Fratamico Chief Business Officer

Apr 11, 2011 8:00am EDT

Trevena Initiates Phase 2 Study of TRV120027 for Acute Heart Failure

Feb 23, 2011 8:00am EST

Trevena CEO to Present at the 2011 BIO CEO and Investor Conference

Feb 11, 2011 11:59am EST

Trevena CEO, Maxine Gowen, Ph.D., Named "Best Executive" at Annual Stevie(R) Awards Ceremony

Nov 18, 2010 7:00am EST

Trevena CEO to Present at the 2010 UBS Global Life Sciences Conference

Sep 16, 2010 4:00pm EDT

Trevena Presents Preclinical Data for TRV120027, a Biased AT1R Ligand, at the 14th Annual Heart Failure Society of America Meeting

Sep 13, 2010 7:00am EDT

Trevena Secures $35 Million in Series B Funding to Progress Portfolio of GPCR Biased Ligands and to Complete Phase 2 Study of TRV120027 for Acute Heart Failure

Jul 14, 2010 7:00am EDT
RSS
  • Prev
    • 1...
    • 22
    • 23
    • 24
    • 25
    • 26
    • 27
    • 28
    • 29
    • 30
    • 31
    Next
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
    © 2023 Trevena, Inc. All Rights Reserved.
    Privacy Policy Terms of Use Disclaimer Sitemap